Positive Phase 2b Results Unveiled in Atopic Dermatitis, Pruritus Treatment
B244 demonstrated significant levels of efficacy in patients with mild-to-severe atopic dermatitis and itch.
ADORING 1 Study Reveals Promising Results for Tapinarof in Atopic Dermatitis
New data from Dermavant showed high levels of efficacy and statistical significance for the topical cream, which is expected to have an sNDA on file with the US FDA in early 2024.
FDA Approves Skinvive by Juvederm for Improving Skin Smoothness
Previous research demonstrated the microdroplet injection’s ability to improve skin quality, smoothness, and overall hydration.
Exposure to Heavy Traffic Affects Risk of Atopic Dermatitis
Researchers linked proximity to heavy traffic roadways and risk of atopic dermatitis.
Safety, High-Level Details Among Deciding Factors for AD Trial Participation
Patients with atopic dermatitis were asked to rate the importance of several factors that may influence their decision to participate in a clinical trial.
Preparing Patients for the Summer Sun: Location, Location, Location
Leading clinicians discuss sun protection best practices based on weather, climate, and travel needs.
Preparing Patients for the Summer Sun: Special Issues in Photosensitivity
Leading clinicians discuss sun protection and special issues in photosensitivity.
Preparing Patients for the Summer Sun: Derms Debunk 5 Sunscreen Myths
Leading clinicians debunk 5 of the most common sunscreen myths.
Preparing Patients for the Summer Sun: Discussing Sun Protection
Leading clinicians discuss sun protection best practices and recommendations for the upcoming summer months.
Addressing Skin of Color Disparities in Cosmetic Dermatology
Elaine Kung, MD, FAAD, discusses advancements in energy-based devices and the ways physicians in the dermatology space can advance their standard of care for patients with skin of color.
Mesoderm Therapy, Compound Glycyrrhizin Improves Rosacea and Patient Satisfaction
Researchers investigated the effects of combination mesoderm therapy and compound glycyrrhizin injections in patients with rosacea.
Gender-Affirming Hormone Treatment Does Not Impact Skin Cancer Incidence
In a large cohort of transgender patients, gender-affirming hormone therapy did not have an effect on the incidence of skin cancers.
Oxymetazoline Efficacious in Reducing Rosacea-Associated Facial Erythema
When compared to a vehicle treatment, patients with rosacea being treated with oxymetazoline had a more significant reduction facial erythema.
Anxiety Prevalent in Dermatology Outpatients
Several dermatologic conditions are known to be associated with anxiety disorders or mental health concerns.
Metformin and Doxycycline Demonstrate Equal Efficacy in Acne Treatment
Researchers said doxycycline, however, was more efficacious in reducing inflammatory lesions.
Examining Comorbidities in Vitiligo
The pigment disorder is associated with several autoimmune and systemic comorbidities.
Vitamin D Lower, Basophil and Eosinophil Counts Average in Vitiligo Patients
Researchers compared counts between patients with vitiligo and a control group of patients.
First Case Report of Vitiligo Triggered by Dupilumab Treatment
Researchers have identified what may be the first report of vitiligo induced de novo by dupilumab therapy.
Addressing Disparities in Atopic Dermatitis Through Teledermatology
Adam Friedman, MD, FAAD, discusses his RAD 2023 session, "Using Teledermatology to Reduce Disparities in Atopic Dermatitis."
Ruxolitinib Cream Provides Substantial, Sustained Itch Relief in AD Patients
A single-site study involving an adult cohort with atopic dermatitis saw significant itch improvement.
Discussing Disparities in AD With Andrew Alexis, MD, MPH
Alexis discusses his Revolutionizing Atopic Dermatitis session, “Disparities in the Care of Atopic Dermatitis in the United States.”
Digital Educational Intervention Increases Awareness Among Hispanic Patients With AD
The study examined the impact of an educational intervention on the population with the highest prevalence of the disease.
Dupilumab Efficacious in Pediatric Patients as Young as 6 Months
The drug was both safe and effective in patients ages 6 months to 5 years.
Revolutionizing Atopic Dermatitis Recap: Day 3
Catch up on coverage from the third day of Revolutionizing Atopic Dermatitis.
Abrocitinib Has Acceptable Long-Term Safety Profile in Adolescents with AD
Researchers determined there were no unique safety concerns in the study, which spanned 1000 patient years.
Crisaborole Ointment Leads to Significant, Consistent Improvements in AD
In a cohort of Chinese and Japanese pediatric patients, researchers deemed the topical treatment both safe and effective.
Lebrikizumab Efficacious in Clearing Hand, Facial Atopic Dermatitis
In 3 phase 3 clinical trials, the drug demonstrated significant improvements of AD when compared to a placebo.
No Differences in Severity or Treatment Among Racially Diverse Eczema Patients
In a diverse, urban cohort, researchers did not find discrepancies between disease severity or prescribed treatment.
Revolutionizing Atopic Dermatitis Recap: Day 2
Catch up on coverage from the second day of Revolutionizing Atopic Dermatitis.
Systemic Treatment, Immunosuppressants, and JAK Inhibitor Session Highlights
Jonathan Silverberg, MD, PhD, MPH, shares highlights and key takeaways from his RAD 2023 sessions.